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ABSTRACT
Objective: To identify differences in the range of medicines available and
subsidized for ambulatory care in Finland and New Zealand.
Methods: Medical entities listed in national product information sources
and their subsidy statuses were compared. The number and overlap of
entities available and subsidized were determined. Differences in the age of
subsidized medicines were compared using the date of ﬁrst registration.
Differences in licensing delays were compared using a selection of new
innovative medicines that provide health gain.
Results: Within the inclusion criteria, 779/763 entities were available and
495/471 subsidized in Finland/New Zealand, of which around 30%
(30.9% Finland, 29.5% New Zealand) were not available and approxi-
mately 40% (41.4% Finland, 38.4% New Zealand) not subsidized in the
other country. The proportion of fully subsidized entities was higher in
New Zealand (86.2%/29.1%). The entities only subsidized in New
Zealand were signiﬁcantly older than those only subsidized in Finland and
the share of licensed and launched innovative medicines was signiﬁcantly
smaller in New Zealand. The differences were equally distributed across
the therapeutic groups but clinically relevant differences were rarely
found.
Conclusions: In New Zealand, medicines are heavily subsidized across
therapy groups, but those uniquely subsidized were older entities. In
Finland, more “newer” medicines are subsidized and available, but the
level and coverage of subsidy is lower and thus, the patient cost burden is
higher. The cost containment policies adopted seem to affect patients’
access to medicines mainly by availability in New Zealand and by afford-
ability in Finland.
Keywords: access to medicines, cost containment policies, cross-national
comparison, drug utilization, Finland, New Zealand, pharmaceutical
policy, prescription medicines.
Introduction
Finland and New Zealand are relatively small countries within
the Organisation for Economic Co-operation and Development
(OECD) that have similar public health problems and heath-care
systems. Both countries have publicly funded health care with
universal coverage (based on the Beveridge model) and low share
of health-care funding from private insurance (2% in Finland
and 5% in New Zealand in 2005) [1–3].
Total health expenditure per capita (adjusted by purchasing
power parities) grew almost identically in the two countries
during the past 3 decades, as did pharmaceutical expenditure in
the 1980s and early 1990s [3,4]. However from 1995 to 2005,
pharmaceutical expenditure grew more slowly in New Zealand
(2.5%) than in Finland (5.0%) and substantially less than in
OECD countries on average (4.6%). At the end of the period,
in 2005, period, the total pharmaceutical expenditure per
capita was US$380 (purchasing power parity (PPP)) in Finland
and US$290 (PPP) in New Zealand, although total health
expenditure per capita was very similar (US$2331 [PPP] in
Finland and an estimated US$2343 [PPP] in New Zealand).
The public share of pharmaceutical expenditure in 2005 was
10% lower in Finland (56%) than in New Zealand (66%)
although the public share of total health expenditure was 78%
in both countries [3,4].
It is likely that the different cost containment policies adopted
in Finland and New Zealand have contributed to the different
growth rates in pharmaceutical expenditure. Since the establish-
ment of New Zealand’s Pharmaceutical Management Agency
(PHARMAC) in 1993, growth in pharmaceutical expenditure
has decreased [4,5]. Cost containment controls differ from those
in Finland. In New Zealand, a range of strategies were used,
including reference pricing of therapeutic groups, tendering,
generic substitution by pharmacists [6] and in Finland, generic
substitution by pharmacists and indirect control of wholesale
prices by cost-effectiveness-based subsidy decisions [7,8]. In New
Zealand, PHARMAC is not only in charge of reimbursement
decisions and pharmaceutical budget, but also directly involved
in negotiating purchasing contracts with suppliers. In Finland,
reimbursement decisions and reimbursement administration is
done separately by the Pharmaceutical Pricing Board (under the
Ministry of Social Affairs and Health) and the Social Insurance
Institution, respectively. Neither is directly involved in the pur-
chase of medicines.
Pharmaceutical cost containment policies may have a nega-
tive impact on patients’ access to medicines. The launch of new
medicines is likely to be delayed in countries with small potential
sales volumes and low expected prices resulting from cost con-
tainment policies [9], and higher patient costs may reduce all
health-care usage, have negative health outcomes on people with
low incomes, but have little or no effect on health on average
[10–12]. In cost comparisons, patients’ out-of-pocket payments
and retail prices were found to be high in Finland when com-
pared with other European countries [13–15], although the
wholesale prices were moderate [15].
Address correspondence to: Katri Aaltonen, Department of Social Phar-
macy, University of Kuopio, P.O. Box 1627, FIN-70211, Kuopio, Finland.
E-mail: katri.aaltonen@uku.ﬁ.
10.1111/j.1524-4733.2009.00598.x
Volume 13 • Number 1 • 2010
V A L U E I N H E A LT H
148 © 2009, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/10/148 148–156
In both countries, the medicines are subsidized according a
positive list updated monthly [16,17]. Medicines can be fully or
partly subsidized (see details in Table 1). Individual patient’s
medicine costs can vary substantially in both countries when
subsidy levels, annual price caps, and prices for nonsubsidized
medicines are taken into account, making direct comparisons
difﬁcult. Although in general, patient costs are lower in New
Zealand, with higher general subsidy and an annual price cap of
about a quarter of that of Finland (even if adjusted by 2007
OECD estimated PPPs [18]). In addition, low income people,
children, and high health-care users are exempt from or have
reduced copayments in New Zealand, whereas no patient group
receives a general exemption from payments in Finland. After
reaching the annual caps, however, prices in New Zealand can be
higher if part-subsidized medicines are used.
As a percentage of annual average income, the patient con-
tribution seems high in Finland. According to Statistics Finland
[19], the average income in Finland was €22,621 (2006, average
income per income recipient) of which the annual price cap was
2.8%. In New Zealand, the corresponding ﬁgure was
NZ$31,720 (2006, from average weekly income for all people
from all sources) according to Statistics New Zealand [20], and
the price cap thus, was only 0.95% of the annual average
income. Nevertheless, inequality as measured by the Gini coefﬁ-
cient was 26.1 in Finland (well below the OECD average),
whereas New Zealand was clearly above the average with 33.7
[21].
In-patient medicines also affect the range of subsidized medi-
cines available to patients. Medicines used for hospital
in-patients are funded from hospital budgets in both countries
without cost to the patient. Medicines for treatment of accidents
can be paid for by a speciﬁc social insurance scheme, the Acci-
dent Compensation Commission, in New Zealand, and this is
also the case in Finland for road accidents. In very rare cases in
New Zealand, medicines not listed in the Pharmaceutical Sched-
ule can be funded on a case-by-case basis under exceptional
circumstances-policies [16]. Social welfare can fund some medi-
cines for very low- or no-income patients in both countries.
Each country’s pharmaceutical system has been criticized
from within. In Finland, there has been concern over the effect of
high costs on access to medicines, especially for people with low
incomes [7,22]. In New Zealand, the debates concern the lack of
new and allegedly more efﬁcient or safe subsidized medicines
[23,24]. As both OECD countries are of similar size and have
similar public health problems and publicly funded health care,
an examination and comparison of access to medicines in these
two countries is of interest internationally.
Aims of the Study
The aims of the study are to examine and compare the range of
medicines available and subsidized for ambulatory care in
Finland and New Zealand in 2007 and to further analyze the
differences found by: 1) the age of the medicines subsidized solely
in each country (using years since ﬁrst marketed in reference
countries); 2) clinically relevant differences in the three largest
anatomical therapeutic chemical (ATC)-groups; and 3) delays in
licensing and launch of new innovative medicines that provide
health gain.
Methods
Data Sources
The range of medicines for ambulant patients in Finland and
New Zealand was compared using published national product
information sources by a method modiﬁed from that of Chui
et al. [25]. For New Zealand, the printed version of MIMS New
Ethicals 2007 Issue 6 (January–June) [26] was used as primary
source. Additional product information was gathered from
Medsafe online Datasheets [27]. Subsidy information was gath-
ered from the published version of the New Zealand Pharmaceu-
tical Schedule June 2007 version [16]. For Finland, the “desk
reference” used was the printed version of Pharmaca Fennica
2007 (PF2007) [28]. The subsidy information, as well as addi-
tional product information were extracted from an electronic
report (Unicode ﬁle) received for research purposes from the
Association of Finnish Pharmacies, containing ATC codes, price,
and subsidy information from June 2007. The original sources of
Table 1 Reimbursements of outpatient pharmaceuticals in Finland and New Zealand in 2007
Finland New Zealand
Subsidized items Positive list, updated monthly. Separate positive lists for 42%/72%/
100% subsidized medicines.
Positive list, updated monthly (called the Pharmaceutical Schedule)
General subsidy Unrestricted 42% of retail price Unrestricted 100% subsidy with ﬁxed copayment (US$0–11.10 per
item, in most cases US$2.22 per item)*
Other subsidies Restricted 42% subsidy of retail price by prior application for
patients meeting speciﬁc criteria (very expensive medicines).
Seventy-ﬁve percent of retail price by prior application for speciﬁc
list of medicines for patients with severe and chronic conditions
(e.g., asthma, hypertension)
One hundred percent subsidy with ﬁxed copayment (US$4.03
per item) by prior application for speciﬁc list of medicines for
patients with severe and life-threatening conditions (e.g., cancer,
diabetes)
Part subsidy for speciﬁed medicines for which the price exceeds
the government subsidy. Patient pays ﬁxed copayment plus
manufacturer’s surcharge (subsidy decided on a case-by-case basis
by the PHARMAC).
Special Authority medicines (full or part subsidized). Restricted by
prior authorization.Applications can be made for patients
meeting speciﬁc criteria.
Annual cap US$843.06 for subsidized medicines per person, after which a ﬁxed
copayment applies (US$2.02 per item).§
Twenty prescription charges per family or over 12 visits to a doctor
(theoretical maximum copayment US$221.92) after which the
level of copayment is reduced (US$ 0–2.22 per item).†‡
Exemptions None Children under 6 years are exempt from copayments. Patients on a
low income are entitled to a copayment reduction (maximum
US$2.22 per item).
*Level of copayment depends on the prescriber, pharmacy, patient’s incomes, and health service use.
†Manufacturer’s surcharge applies.
‡Medicines outside positive list are not subsidized.
§Medicines outside positive list are not subsidized.
The prices have been converted to US dollars from national currencies (Euro, New Zealand dollar) with the exchange rate at time of analysis (June 1, 2007/European Central Bank [44]).
PHARMAC, Pharmaceutical Management Agency.
Range of Medicines Available and Subsidized 149
the data were the National Agency for Medicines for the general
information and ATC-codes, the Social Insurance Institution, and
the Pharmaceutical Pricing Board for subsidies, and pharmaceu-
tical industry for prices.
For the analysis of the launch delays, a list of new important
medicines that provide health gain was gathered as published by
Roughead et al. [29] using medicines classiﬁed by the United
States Food and Drug Administration (US FDA) [30] and the
Canadian Patented Medicines Prices Review Board [31], exclud-
ing all combination products and products that were not new
molecular entities.
Data Management
The medicines were coded with full ATC-code (developed by the
WHO Collaborating Centre for Drug Statistics Methodology,
ATC index 2007). Where classiﬁcation was not available in the
2007 version of the index, classes from the 2008 index were
added [32]. Where class was available in the ATC-code system
but active ingredient was not, the International Nonproprietary
Names (INN) from Martindale [33] was used. Where obvious
classes were not available, similar classiﬁcation and naming was
done in both countries. Products registered as medicines in New
Zealand, but as foods, other medical supplies, or natural rem-
edies in Finland were classiﬁed in V03, other therapeutic prod-
ucts, and are therefore excluded (see Inclusion/Exclusion
Criteria). Products listed in the Finnish PF2007, but not licensed
as medicines were excluded, although medicines listed as being
temporarily licensed were included. From New Zealand, prod-
ucts listed as being available under section 29 of the Medicines
Act 1981 (unregistered medicines approved for use by medical
practitioners) were included.
Products were classiﬁed in six subsidy groups according to
subsidy level (part or full) and subsidy restrictions (restricted or
unrestricted) and any combinations of these (e.g., full subsidy
with restrictions but part subsidy for all). For consistency, prod-
ucts that were subsidized in New Zealand only in extemporane-
ous products or only when distributed by primary or secondary
health-care providers (e.g., inﬂuenza vaccines) were classiﬁed as
unsubsidized. All products that had more than one active ingre-
dient were classiﬁed as combination products.
First registration years were identiﬁed from publicly available
online databases of regulatory agencies [31,34–40].
The raw data were entered in MS Excel. The collapsing and
merging of data sets and statistical analyses were performed in
STATA (version 8.0) (StataCorp LP, College Station, TX).
Inclusion/Exclusion Criteria
ATC classes A11 (vitamins), A12 (mineral supplements), B05
(blood substitutes and perfusion solutions), D02 (emollients
and protectives), and V (various) were excluded from analyses
because of the high percentage of multiple ingredient products
that prevented a meaningful comparison.
Medicines used in the treatment of HIV, hepatitis, and tuber-
culosis in ATC classes J and L were excluded from all analyses. In
Finland, these medicines are funded under a speciﬁc legislation
(Communicable Diseases Act 538/1986, Act on Social and
Healthcare Client Charges 734/1992) and are dispensed from
hospitals free of charge. Therefore their subsidy status was not
available for comparison.
Products only indicated for use as infusions were excluded
because information on their outpatient use and thus, funding,
was limited and could not be compared. All combination prod-
ucts were excluded from the analyses. To avoid losing entities
only subsidized in combination products in one country, all enti-
ties only subsidized in one country were checked for subsidized
equivalents among the combination products from the other
country. A total of 11 such entities were found and these were
considered as subsidized in both countries and excluded from
analysis of the age of entities.
Data Analysis
Similarity of range of medicines. The number of listed and sub-
sidized medical entities, as well as fully subsidized entities was
determined for both countries. The entities included were then
classiﬁed in the following eight groups:
1. Listed and subsidized in both countries;
2. Listed but not subsidized in both countries;
3. Listed in both countries but only subsidized in Finland;
4. Listed in both countries but only subsidized in New
Zealand;
5. Listed and subsidized in Finland, not listed in New Zealand;
6. Listed and subsidized in New Zealand, not listed in Finland;
7. Listed but not subsidized in Finland, not listed in New
Zealand; and
8. Listed but not subsidized in New Zealand, not listed in
Finland.
The number of entities in each group was determined. Deter-
mining the subsidy status for entities in the ATC index class L
(antineoplastic and immunomodulating agents) was problematic
because policies and cost-sharing between primary and second-
ary care differed between the two countries. Therefore, two
analyses were performed, one with and the other without the
ATC class L, to provide a sensitivity analysis.
Differences by therapeutic groups. The number of medical enti-
ties listed and subsidized in different therapeutic groups was
determined, as was the overlap and difference within the thera-
peutic groups.
To evaluate the clinical relevance of the differences in
numbers (e.g., whether the difference in numbers of entities was
only due to subsidizing different therapeutic alternatives), the
three largest ATC-therapeutic groups by number of entities avail-
able and subsidized were chosen for further analysis. Each fourth
level ATC-subgroup (chemical subgroup) containing at least one
available entity within inclusion criteria in either country was
compared for subsidized entities in the two countries. Subgroups
that had subsidized entities only in one of the countries were
identiﬁed.
Differences in subsidizing old and new medicines. All entities in
analysis groups 3 to 6 (i.e., those that were only subsidized in one
of the countries) were analyzed to determine their “age” to
further evaluate the cause of the difference in numbers found
between the two countries. Each medical entity (or formulation
of an entity bearing a different ATC-code) was checked for their
ﬁrst year of registration in 1 to 4 reference countries and classi-
ﬁed by earliest year found. The number of reference countries
used increased for newer medicines as follows:
1. Entities were ﬁrst searched for their earliest year of regis-
tration in Finland or in New Zealand. Those ﬁrst registered
before 1970 in either country were classiﬁed by the earliest
identiﬁed year.
2. Newer entities were searched for their earliest year of regi-
stration in another country (Finland or New Zealand
depending on the previous search). Entities ﬁrst registered in
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the period 1970 to 1979 according to these two references,
were classiﬁed by the earliest identiﬁed year of registration.
3. Entities registered in Finland and New Zealand on or after
1980 were checked for ﬁrst year of registration in at least
two other reference countries: the United States, the Euro-
pean Union (EU) or France, Canada, and Sweden in that
order until at least two additional registration years were
found. They were then classiﬁed according the earliest iden-
tiﬁed year in any of the countries. Entities that were not
registered in more than one of the countries mentioned were
classiﬁed according to the earliest year of registration
identiﬁed.
The sources of registration years were the US FDA Electronic
Orange book [34], the Canadian PatentedMedicine Prices Review
Board Annual Reviews [31] and the online product databases of
national regulatory agencies in New Zealand [35], France [36],
Finland [37], and Sweden [38]. The EuropeanMedicines Agency’s
database of the European Public Assessment Reports was also
used as a secondary source [39], but EU registration dates were
primarily collected from the French database due to the technical
advantages of their search engine. The FDA Orange book only
contained detailed information starting from the year 1982 and
for biological products from2004 and therefore another FDAweb
database, Drugs@FDA, [40] was used as secondary source. All
years preceding 1960 were rounded to 1960.
The ﬁrst year of registration as previously classiﬁed was used
to indicate the age of the entity. The mean, median, and percen-
tiles (25% and 75%) were determined for each country and
tested for statistically signiﬁcant difference using STATA. Because
the newer medicines were checked in a more comprehensive
manner, it is possible that some entities were actually older than
their classiﬁcation, but it is unlikely that they were newer.
Delay in launching new important innovation products that
provide health gain. The registration status in New Zealand and
Finland was sought from regulatory authority’s web pages
[35,37] for all 57 identiﬁed innovative products described in a
previous section (Data Sources). The number of new innovative
products registered before June 1, 2007 in the two countries was
determined. To compare the launch status, the listing of these
entities was searched from national desk references in 2007 (see
Data Sources). The proportions of these products registered and
listed were determined for each country and tested for statisti-
cally signiﬁcant difference.
Results
Similarity of Range of Medicines
After exclusions of combinations, infusions, and medicines for
severe contagious diseases, there were 779 entities in Finland and
763 in New Zealand. From the entities listed in Finland, 241
(30.9%) were not listed in New Zealand and from those listed in
New Zealand, 225 (29.5%) were not listed in Finland (Table 2,
Fig. 1). Of the 495 entities subsidized in Finland, 205 (41.4%)
entities were not subsidized in New Zealand, and of the 471
entities subsidized in New Zealand, 181 (38.4 %) were not
subsidized in Finland. In New Zealand, 86.2% of the subsidized
entities were fully subsidized whereas only 29.1% were fully
subsidized in Finland (Table 2). Furthermore, in Finland, all fully
subsidized entities had restrictions on the subsidy although in
New Zealand, the majority were subsidized without restrictions.
It should be noted, however, that nearly all medicines in Finland
that were fully subsidized with restrictions were partly subsidized
without restriction for those not meeting the criteria, whereas in
New Zealand, those not meeting the criteria had to pay the full
cost.
The number of entities in different analysis groups including
and excluding class L entities were similar with all differences
between countries within 1%. Therefore, the results do not
appear to be sensitive to including or excluding entities in ATC
class L.
Differences in Therapeutic Groups
Differences between the countries in the number of entities avail-
able and subsidized in different ATC categories were small
(Fig. 2).
There were differences in all therapeutic groups and differ-
ences in the number of entities available and subsidized followed
similar patterns. The results indicate that differences in the range
of medicines are not limited to particular therapeutic groups but
occur throughout the groups.
Groups A, C, and N had the most entities, both available and
subsidized, and so were selected for further analysis. When pos-
sible, the ATC fourth level chemical subgroups were compared
and therefore their names are used. In cases, however, where the
subgroup only contained one entity, the entity name is used. If all
the fourth level subgroups had similar results, the name and code
of the level above was used. Unique entities were also compared
in chemical subgroups named “others” where entities were not
necessarily therapeutic alternatives. More in-detail listings of
entities and their availability/subsidy statuses in the two coun-
tries are available upon request from the authors.
In ATC group A (alimentary tract and metabolism), many
subgroups contained subsidized alternatives in both countries or
in neither country. Those subgroups, however, where subsidized
entities were only available in New Zealand, contained predomi-
nantly older and cheaper entities. These were triamcinolone
(A01AC), choline salicylate and benzydamine (A01AD), most
antacid subgroups (A02AB/C) as well as bismuth subcitrate
and sucralfate (A02BX), drugs for functional bowel disorders
(A03A), butylscopolamine (A03BB), scopolamine (A04AD),
most laxative subgroups (A06AB/G/X), medicinal charcoal
(A07BA), antipropulsives (A07D), intestinal antiallergic agents
(A07EB), and acarbose (A10BF). Subgroups where subsidized
entities were only available in Finland contained mainly newer
and more expensive medicines. These were antiobesity prepara-
tions (A08), guar gum, repaglinide and nateglinide in group
A10BX, and orphan drugs mercaptamine, nitisinone and
miglustat in group A16.
Table 2 Number and overlap of entities by country
Finland
New
Zealand
Extent of overlap
(i.e., number of
entities in common
in the two countries)
Number of listed medical
entities or combinations
of entities*
1046 1007 647
Number of entities
included in the study†
779 763 538
Number of subsidized
entities (any level)
495 471 290
Number of fully subsidized
entities (fully subsidized
without restrictions)
144 (0) 406 (326) 108
*Excluding anatomical therapeutic chemical (ATC) classes A11 (vitamins), A12 (mineral
supplements), B05 (blood substitutes and perfusion solutions), D02 (emollients and protec-
tives), and V (various).
†Excluding medicines used in the treatment of HIV, hepatitis, and tuberculosis in ATC classes
J (antiinfectives for systemic use) and L (antineoplastic and immunomodulating agents),
medicines only indicated for use as infusions and combination products.
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The ATC group C (cardiovascular system) followed a similar
pattern. A few subgroups containing older entities only had
subsidized options in New Zealand (mexiletine [C01BB], perhex-
iline [C08E], and nicotinic acid derivates [C10AD]).Within group
C02 (other) antihypertensives only New Zealand had subsidized
options in few subgroups containing older entities (methyldopa
[C02AB], hydralazine [C02DB]), only New Zealand had subsi-
dized options, whereas relatively expensive bosentan (C02KX)
was only subsidized in Finland. More subsidized options were
available in New Zealand in the groups of peripheral vasodilators
(C04) and vasodilators (C05), both containing older entities. In
subgroups of cardiac therapies (C01), beta-blocking agents (C07),
calcium channel blockers (C08), and agents acting on the renin-
angiotensin system (C09), the range of newer entities was wider in
Finland (e.g., selective beta-blocking agents [C07AB], selective
calcium channel blockers [C08C], angiotensin II antagonists
[C09C], HMG CoA reductase inhibitors [C19AA]), but subsi-
dized alternatives were available in New Zealand.
Similar results were found in ATC group N (nervous system).
Under N02 (analgesics), few differences were found within older
entities (dextropropoxyfene and tramadol were only subsidized
in Finland and acetylsalicylic acid, nefopam, and older antimi-
graine preparations [group N02CX with pizotifen, clonidine]
were only subsidized in New Zealand). Within antiepileptics
(N03) and anti-Parkinson’s agents (N04), few newer entities
were only subsidized in Finland (e.g., levetiracetam, pregabalin in
group N03AX) and some subgroups containing older entities
only had subsidized options in New Zealand (ethosuximide
[N03AD], orphenadrine chloride [N04AB], benzatropine
[N04AC], amantadine [N04BB]). Within neuroleptics (N05A),
indole derivates (N05AE), and sulpride (N05AL), as well as
aripriprazole (N05AX), were only subsidized in Finland, and
tetrabenazine (N05AK) was only subsidized in New Zealand.
Within hypnotics and sedatives (N05C), only New Zealand sub-
sidized aldehydes and derivates (N05CC). Among antidepres-
sants (N06A), nonselective MAO-inhibitors (N06AF) were only
subsidized in New Zealand, and in group N06AX (other antide-
pressants), there were more subsidized options in Finland (traz-
odone, mirtazapine, milnacipran, reboxetine, duloxetine).
Antidementia medicines (N06D) were not subsidized at all in
New Zealand but were in Finland. Expensive medicines riluzole
and hydroxybutyric acid (sodium oxybate) in group N07XX
were only subsidized in Finland.
Although speciﬁc entities are used as examples here, trends
rather than single missing items can be considered as relevant
Figure 1 The medical entities available and subsi-
dized in Finland and New Zealand. The larger
circles represent the medicines available and the
smaller circles the medicines subsidized.The pro-
portions of the sections are not to scale. The
numbers of the analysis groups are in brackets
followed by the number of entities in each group.
Figure 2 Differences in therapeutic groups. The medical entities in different
ATC therapy groups, available (A) and subsidized (B), by country. The lightest
part of each column presents the entities available or subsidized in both
countries and the darker parts the entities uniquely available or subsidized in
one country. The letters on the x-axis represent the ATC-groups according to
the WHO ATC-index:A, alimentary tract and metabolism; B, blood and blood
forming organs; C, cardiovascular system; D, dermatologicals; G, genitourinary
system and sex hormones; H, systemic hormonal preparations, excluding sex
hormones and insulins; J, antiinfectives for systemic use; L, antineoplastic and
immunomodulating agents; M, musculoskeletal system; N, nervous system; P,
antiparasitic products, insecticides and repellents; R, respiratory system; S,
sensory organs.
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results from this analysis, because not all available or subsidized
entities might be listed in the sources used. Even so, in all ana-
lyzed subgroups, three main differences were identiﬁed:
1. Subgroups with several commonly used, relatively new, and
very similar molecules (some also called “me, too”-drugs)
had a wide choice of subsidized options in Finland but at
least few subsidized options were also available in New
Zealand (e.g., SSRIs, angiotensin II antagonists, 5HT-
agonists, statins). In these groups some entities had already
generic competition.
2. Subgroups with only expensive, patent protected new enti-
ties, very expensive medicines for rare conditions, and
orphan drugs often had no subsidized options in New
Zealand (e.g., antidementia medicines, anti-obesity medi-
cines, meglitinides, indole derivates, nitisinone, miglustat,
bosentan, hydroxybutyric acid, aripiprazole, levetiracetam).
3. Subgroups that had subsidized options only in New
Zealand often contained either very old entities (ﬁrst regis-
tered on or before 1960s) no longer used in Finland (e.g.,
tolbutamide, imipramine, phenelzine, pizotifen) or cheaper
entities for treatment of milder conditions, or symptoms
(e.g., laxatives, antacids, antipyretics, analgesics).
The higher subsidies in Finland were restricted to severe
conditions (e.g., 100% subsidy for diabetes, psychosis, epilepsy,
Parkinson’s disease and 72% subsidy for colitis ulcerosa,
Crohn’s disease, several chronic conditions of the cardiovascular
system, etc.). Furthermore, additional restrictions were also in
place, for example, medicines for depression were only 100%
subsidized in severe cases with psychotic symptoms. In New
Zealand, there were fully subsidized options across nearly all
therapy groups but the newer and more expensive medicines
were only subsidized by prior application for patients who fail to
tolerate or beneﬁt from other options (e.g., angiotensin II ago-
nists, long-acting insulin analogues).
Differences in Subsidizing Old and New Medicines
The 386 entities in analysis groups 3–6 (i.e., medicines that were
subsidized in only one country) were classiﬁed by their ﬁrst year
of registration (Fig. 3). The majority (80.7%) of entities only
subsidized in New Zealand were older entities ﬁrst registered
before 1980 whereas only 18.5% of the Finnish entities were in
this category. Of the medicines only subsidized in Finland, 65.3%
were ﬁrst registered in 1990 or later but only 4.4% of the New
Zealand entities were in this category.
Because the results were not normally distributed, a nonpara-
metric test was chosen (Wilcoxon signed-rank or Mann–Whitney
U test). The results were highly signiﬁcant (P < 0.001) and exclu-
sion of ATC class L did not change the results. Because other
subsidized entities were available in both countries, it appears
that the difference in the range of subsidized medicines between
the two countries results from New Zealand subsidizing signiﬁ-
cantly older medicines than Finland.
Delay in Licensing and Launching Important Innovative
Products that Provide Health Gain
From the listed 57 new innovative medicinal entities, 47 were
registered in Finland and 33 in New Zealand before June 1,
2007. The difference in licensing and launching was consistent
between the countries. Thirty-seven entities were listed in Finland
and 22 in New Zealand in the national published product infor-
mation sources in 2007 (Fig. 4). Thus, 29% more were registered
and 40% more were launched in Finland according to the
sources used. The differences between the two countries were
also statistically signiﬁcant with P < 0.05 (Fisher’s exact test).
Discussion and Conclusions
In this article, a new method for cross-national comparison is
introduced. The comparison of the available and subsidized
range of medicines adds one piece to the puzzle of the complex
question of patients’ access to medicines. The strengths of the
method presented were that almost the entire range of medicines
was compared and thus, unlike other studies, the results were not
Figure 3 Differences in the age of medical entities only subsidized in either of
the countries.Medical entities meeting the inclusion criteria and only subsidized
in Finland or New Zealand, classiﬁed by their age by oldest identiﬁed date of
registration. N = 205 (Finland) and 181 (New Zealand). Mean year of registra-
tion: 1990 (Finland), 1972 (New Zealand). Percentiles (25%/50%/75%): 1986/
1994/1999 (Finland), 1967/1969/1977 (New Zealand). The difference was
statistically signiﬁcant (P < 0.001, Mann-Whitney U test).
Figure 4 New innovative medicines. Registration and launch status in Finland
and New Zealand of 57 new innovative medicines that provide health gain [29].
The columns on the left represent medicines registered before June 1, 2007 and
on the right, medicines listed in printed product information sources by 2007.
The differences between the countries were statistically signiﬁcant (P < 0.05,
Fishers’s exact test).
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inﬂuenced by any selection criteria [41]. Furthermore, three dif-
ferent approaches were used to deﬁne the causes of identiﬁed
differences.
The present study found that the number of medical entities
available and subsidized in the two countries was very similar.
There was, however, a considerable difference between the enti-
ties uniquely available and subsidized in the two countries. In
numbers, around 30% (30.9% in Finland and 29.5% in New
Zealand) of the medical entities in each country were not avail-
able in the other, and approximately 40% (41.4% in Finland and
38.4% in New Zealand) of the entities subsidized in each country
were not subsidized in the other. There was also a substantial
difference between the numbers of fully subsidized entities.
Nearly all subsidized entities (90%) were subsidized in full in
New Zealand although less than 30% were fully subsidized in
Finland.
The differences between the available and subsidized entities
were evenly distributed across the therapy groups but there was
a signiﬁcant difference between the countries in subsidizing old
and new medical entities. The entities only subsidized in New
Zealand were predominantly older medicines ﬁrst registered in
the 1970s or earlier whereas, those only subsidized in Finland
were mostly newer entities registered on or after 1990. The
analysis of drugs within therapeutic groups followed the pattern
for medicines as a whole and reﬂects the policies in the two
countries. For example, in Finland, over-the-counter medicines
are only subsidized in rare cases and higher (72% and 100%)
subsidies are restricted to severe and chronic or life-threatening
conditions, although in New Zealand, there is a tendency to
provide at least one fully subsidized medicine in each therapy
group. Accordingly the study found that entities included in
over-the-counter products (less expensive products such as laxa-
tives, antacids, analgesics), were rarely subsidized in Finland, but
there was a wide range of these fully subsidized in New Zealand.
Although usually cheap, these medicines for treatment of milder
conditions and symptoms are subject to free pricing in Finland,
because they are excluded from subsidy. Furthermore, their costs
are not included in the annual price cap.
Among newer and more expensive medicines, the subsidized
range was oftenwider in Finland but therapeutic alternatives were
available in New Zealand (e.g., SSRIs, angiotensin antagonists,
5HT1-agonists, statins) indicating that a large part of the differ-
ence is due to Finland subsidizing more derivative medicines (and
also the so-called “me, too”-drugs). On the other hand, several
subgroups with new and expensive medicines had no subsidized
alternatives in New Zealand at all (e.g., antidementia medicines,
antiobesity medicines, [orphan] medicines used in treatment of
rare conditions). Also, the comparison of the launch status of new
innovative medicines that provide health gain showed that clini-
cally relevant differences do exist. From the selection of 57 new
innovative entities, 29% fewer were registered and 40% fewer
were launched in New Zealand when compared to Finland.
These results are consistent with earlier studies. The high
patient contribution in Finland was demonstrated by Noyce et al.
in a comparison between eight EU countries [14]. Regarding the
age of medicines, two earlier studies by Danzon et al. demon-
strated that the range of medicines in New Zealand was older
than in Germany and in The Netherlands [42], and that New
Zealand ranked among those with the least new entities
launched, and Finland among those with the most [9] in a com-
parison of 25 major markets in the 1990s.
Because the purchasing of medicines is done at the national
level in New Zealand and the government is sharing the eco-
nomic risk with the suppliers, substantial discounts can be
achieved and patients beneﬁt from very low prices for most
prescription medicines. At the same time, the choice of consum-
ers and prescribers is strictly limited by reimbursement restric-
tions. Interestingly at the same time, New Zealand is one of the
only countries in the OECD allowing direct to consumer adver-
tising of prescription medicines (Advertising Requirements of the
Medicines Act 1981 [sections 56 to 62], Medicines Regulations
1984 [regulations 7 to 11]). Even so, it seems that the concern
over launch delays of new medicines is not entirely unfounded,
even among new important innovations. It could not be said,
however, whether the delay is caused by suppliers not applying
for marketing authorization due to the strict cost containment
policies or for some other reason e.g., the isolation of the New
Zealand market.
In Finland, consumers or prescribers are given a much wider
variety of subsidized options enabling individual tailoring of
therapies. Rational prescribing is encouraged with guidelines
rather than restrictions, allowing prescribers to make the ﬁnal
decisions about cost-effectiveness in each case. Nevertheless, as
the government subsidies are generally low, a large share of the
economic risk of introducing new therapies is transferred to the
patient. Furthermore, the Finnish system has not been successful
enough in slowing down the rise in pharmaceutical expenditure,
and therefore new cost-containment policies have been necessary.
In 2006, for example, additional restrictions on subsidizing more
expensive statins were imposed [43]. Most recently, Finland
adopted generic reference pricing in the beginning of 2009
(Amendment 803/2008 on Medicines Act [395/1987]).
A limitation of the design was that the medicines included in
this study were from published product information so it is
possible that a small proportion of available medicines were not
listed and not captured in the analysis. Due to the exclusion of
combination products, unique unsubsidized entities only avail-
able in combinations might also have gone unnoticed, but these
are likely to be few and affect both countries similarly. Further-
more, the possibility of obtaining medicines on a named-patient
basis means that almost any single entity could be available for
an individual patient, if needed. In ambulatory care, however,
under normal conditions, the medicines are usually chosen from
those available and listed in published product information, so
such a list can be considered the range of generally available
medicines for most patients. A limitation concerning the “age”
and launch of new medicines analyses is that the results are
drawn from a speciﬁc selection of entities, which is not intended
to be a representative sample. Therefore, the results should not
be generalized to represent all subsidized medicines in the two
countries and the statistical tests were only used for additional
conﬁrmation that there was indeed a difference between the two
countries.
High burden of costs in Finland can restrict access for some
people and hence, the medicines used by different socioeconomic
groups could differ. This might also be the case in New Zealand,
if medicines outside the subsidy system are chosen, but with
commonly used medicines there seems to be greater equality in
access. Further studies of patient out-of-pocket payments as well
as of differences in medicines used across socioeconomic groups
are needed to better compare the effect of cost-containment
policies on access to medicines in these two countries.
In summary, it seems that for most people in New Zealand,
commonly used medicines are heavily subsidized, but the range
of medicines subsidized is biased toward older entities. In
Finland, the subsidy system enables newer medicines to be used
at least with a partial level of subsidy but in exchange, patients
are expected to bear a high proportion of the cost of everyday
medicines for mild to moderate conditions. At national level,
New Zealand has been more successful in controlling the rise of
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pharmaceutical expenditure, but at the same time, the delays in
patients’ access to new therapies, also among important new
innovations, have not completely been avoided. Finland has been
able to enable more choice for individual tailoring of therapies,
but it seems that it has lead also to rises in patient out-of-pocket
payments.
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